Navigation Links
Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care

PITTSBURGH, Jan. 24, 2012 /PRNewswire/ -- Precision Therapeutics, Inc. has recently expanded their BioSpeciFx® product to include 21 clinically-relevant biomarkers to help physicians with their treatment decisions. This enhances Precision's approach to personalizing cancer care by offering additional molecular markers, including the recently FDA-approved ALK-FISH test. By utilizing BioSpeciFx® results in combination with Precision Therapeutics' ChemoFx® in vitro drug response marker, physicians will receive both molecular and live-cell drug response information about a patient's tumor. Through the integration of these two tests, physicians can create a Comprehensive Tumor Profile, allowing them to more completely define their patient's cancer. In an effort to personalize treatment selection even further, BioSpeciFx® and ChemoFx® tests give physicians the ability to choose from suggested tumor-specific panels or to customize a report for each patient.

"The decision to add new biomarker tests to Precision Therapeutics' Comprehensive Tumor Profile was a direct result of market trends and customer requests," says Sean McDonald, CEO. "Precision is committed to producing multiple products that help physicians make difficult clinical decisions throughout the cancer care continuum. We are in the process of developing several additional tools to help us adhere to our mission of improving the odds of survival and the quality of life for cancer patients."

About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.

Precision's state of the art Comprehensive Tumor Profiling is an integrated straightforward approach combining three core platforms of personalized medicine to capture the total sum of genomic, proteomic and functional information for each patient's cancer through a portfolio of multi-platform tests for cancer treatment in multiple tumor types.

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, over 77,000 patient specimens have been submitted for ChemoFx® testing using 105 unique chemotherapy treatments and combinations.

For more information, visit or


SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
2. Applied Precision Announces New Products for Life Sciences Microscopy at the 110th American Society for Microbiology Meeting in San Diego, CA, May 23-26th.
3. Precision Bearing Technologies Featured at Atlantic Design & Manufacturing Show
4. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
5. Applied Precisions Mobile Imaging Lab Hits the Road for a Cross-Country Journey
6. Clinical Experts Detail How They Use Varians TrueBeam™ Technology to Improve the Precision and Speed of Cancer Treatments
7. Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award
8. Applied Precision Installs a Record Four New DeltaVision OMX Super-Resolution Imaging Systems in Eight Weeks
9. Exempla Saint Joseph Hospital Commences Treating Cancer Patients Using New TrueBeam™ System for High-Precision Image-Guided Radiotherapy and Radiosurgery
10. Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico
11. Applied Precision Scientific Team to Present 3D-SIM Paper at BiOS in San Francisco
Post Your Comments:
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):